2467732-66-5
Chemical Structure
Navepdekinra
Synonym(s): DC-806; LY4100504; S-011806
- CAS No.: 2467732-66-5
- Formula:C33H48FN7O4
- Molecular Weight:625.78
InChIKey: WEXJUHWVWXUMKQ-GVIAMBBFSA-N
SMILES: O=C(C1=CC=NN1CC)N[C@@H]([C@@]2([H])CC[C@@H](CC2)C)C(NC3=C(C=C(C=C3)[C@H](C)[C@@H](NC(CC)=O)C(N4CCN(CC4)C)=O)F)=O
Biological Activity: Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC50 = 10.81 nM). Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Navepdekinra | 98.58% | Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC50 = 10.81 nM). Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.91
HY-148272IL-17A modulator-3 -
Similarity Score 0.75
HY-177129Simepdekinra -
Similarity Score 0.66
HY-139203IL-17 modulator 3 -
Similarity Score 0.48
HY-141535IL-17 modulator 1 -
Similarity Score 0.48
HY-101913IL-17A antagonist 1 -
Similarity Score 0.48
HY-141692IL-17 modulator 4 -
Similarity Score 0.48
HY-141692B(R)-IL-17 modulator 4 -
Similarity Score 0.47
HY-141535AIL-17 modulator 1 disodium -
Similarity Score 0.47
HY-111853MV-1-NH-Me -
Explore the MedChemAI to find more analogs
References
- [1]. Paul R. Fatheree, et al. IL-17 Ligands And Uses Thereof. US20200247785A1.
- [2]. Kim D, et al. Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. Am J Clin Dermatol. 2025 May;26(3):307-320. [Content Brief]
- [3]. Xiaobing Deng, et al. The Critical and Unexpected Role of a Methyl Group in Interleukin-17A Inhibitors. bioRxiv 2025.10.02.680113